Axiom Investors’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-85,177
Closed -$21.6M 124
2021
Q4
$21.6M Sell
85,177
-292,719
-77% -$85.6M 0.4% 51
2021
Q3
$145M Sell
377,896
-375,034
-50% -$138M 2.4% 11
2021
Q2
$177M Buy
752,930
+383,167
+104% +$68.5M 2.85% 9
2021
Q1
$48.4M Buy
+369,763
New +$53.6M 0.88% 36

Other funds holding MRNA

Axiom Investors's MRNA Position: Q1 2022 in Review

Axiom Investors sold out of Moderna (MRNA) in Q1 2022, closing a stake of 85,177 shares — an estimated $21.6M sold.

Axiom Investors first reported a position in MRNA in Q1 2021 and held it in 4 quarters. The position peaked at $177M in Q2 2021. 1,006 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

  • Axiom Investors reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
  • Axiom Investors sold 85,177 Moderna shares in Q1 2022, an estimated $21.6M.
  • Axiom Investors first reported a position in Moderna in Q1 2021 and held it in 4 quarters.
  • Axiom Investors's Moderna position peaked at $177M in Q2 2021.
  • 1,006 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on Axiom Investors's 13F filing for Q1 2022, filed 13 May 2022.